UBS downgrades Banco Bilbao stock rating on valuation concerns By Investing.com

UBS downgraded BBVA to Neutral from Buy and cut its price target to €20.50 from €22.30, implying about 5% upside, as it sees limited room for EPS revisions and valuation expansion. BBVA posted record 2025 net attributable profit of €10.5 billion, up 4.5% year over year, but the bank faces softer catalysts from Turkey disinflation, higher cost of equity, and emerging-market FX/macroeconomic exposure. Barclays also turned more cautious, downgrading BBVA to Equalweight and cutting its target to €20.50.

Analysis

The downgrade is less about a near-term deterioration in operating performance and more about the market running ahead of the bank’s ability to continue re-rating. When a stock has already re-priced from a structural discount toward sector-average valuation, incremental upside usually depends on either a step-up in earnings revisions or a lower cost of equity; UBS is implicitly saying neither is likely to arrive soon. That matters because banks with emerging-market exposure often trade on “macro optionality” that can disappear quickly when FX and rate volatility compress visible returns.

The second-order issue is that BBVA’s mix now looks like a cleaner earnings story but a worse multiple story: improving profitability is being offset by higher perceived risk in Turkey/LatAm and less room for self-help. In that setup, the stock becomes more sensitive to any disappointment in capital return cadence, provision normalization, or FX translation than to headline profit growth. The key catalyst window is the next 1-2 quarters, where management either confirms the plateau in revisions or surprises with a new source of growth outside the current guidance envelope.

The contrarian read is that the downgrade may actually be a relative-value positive for higher-quality European banks with lower emerging-market beta. If BBVA no longer screens as a cheap catch-up trade, capital should rotate toward names with more durable domestic earnings and more visible buyback capacity. That is especially relevant if macro volatility keeps the cost of equity elevated: in that regime, banks with less geopolitical/FX noise deserve a persistent premium, not a discount.

Key Decisions for Investors

• Reduce BBVA exposure on strength over the next 1-3 weeks; the risk/reward looks asymmetric with limited fundamental upside and elevated multiple compression risk if EPS revisions stay flat.
• Pair trade: short BBVA / long SAN for 1-3 months. The setup favors the lower-beta domestic franchise if investors rotate away from EM exposure; target 5-8% relative outperformance for SAN with a stop if BBVA gets a fresh catalyst on guidance.
• For options traders, consider buying BBVA 1-2 quarter put spreads financed by selling out-of-the-money calls. This expresses downside from valuation de-rating while limiting premium outlay if the stock simply churns around sector average.
• Use any post-earnings rally in BBVA to rotate into higher-quality European banks with more stable cost of equity assumptions. The trade works best if FX and emerging-market volatility remain elevated into the next reporting cycle.